Phio PharmaceuticalsPHIO
13F holders, Q2 2024 (June 30)12holders +2
5new positions
3sold out
1famous investor
$0.70avg. 13F price*
At the end of Q2 2024, 12 institutions reported holding Phio Pharmaceuticals Corp. (PHIO) in their 13F filings, up 2 from Q1 2024. 5 opened new positions and 3 sold out. The largest holders were Cetera Investment Advisers ($25K), Geode Capital Management, LLC ($20K) and Vanguard Group Inc. ($17K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Phio Pharmaceuticals Corp.
- CUSIP
- 71880W402
- Latest filing quarter
- Q2 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $44K |
| Exits | 3 | $38K |
All 13F filers, Q1 2024 → Q2 2024: 68,529 shares bought and 50,931 shares sold, net +17,598 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Cetera Investment Advisers | 0.00% | Add +16.4% | 35,416 | $25K |
| Geode Capital Management, LLC | 0.00% | New | 28,136 | $20K |
| Vanguard Group Inc. | 0.00% | No change | 24,380 | $17K |
| Bridgeway Capital Management, LLC | 0.00% | No change | 23,486 | $16K |
| Citadel Advisors | 0.00% | New | 21,691 | $15K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | No change | 14,233 | $10K |
| Two Sigma Securities, LLC | 0.00% | New | 12,457 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +0.6% | 5,732 | $4K |
| UBS Group AG | 0.00% | Add +80.2% | 2,447 | $2K |
| Activest Wealth Management | 0.00% | New | 83 | $57 |
| Bank of America Corp. | 0.00% | New | 38 | $26 |
| BlackRock Inc. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is PHIO's weight in each manager's 13F, not the share of Phio Pharmaceuticals Corp. the manager owns.